# Evaxion A/S Reports Positive Three-Year Phase 2 Trial Results for EVX-01 Melanoma Vaccine

- URL: https://stocks.freetheai.org/news/evaxion-a-s-reports-positive-three-year-phase-2-trial-results-for-evx-01-6280d4
- Published: 2026-10-19T07:00:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:EVAX](https://stocks.freetheai.org/symbols/NASDAQ-EVAX)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Evaxion A/S (EVAX) reported three-year follow-up data from its Phase 2 clinical trial evaluating EVX-01 in patients with advanced melanoma. All patients evaluated at the three-year mark maintained their earlier treatment responses without experiencing tumor progression. Notably, EVX-01 was administered as a stand-alone therapy during the third year, building on previous two-year data that showed a 75% overall response rate and a 25% complete response rate.

The findings highlight sustained disease control for the experimental cancer vaccine, demonstrating its potential efficacy even after transitioning away from combination therapy. The long-term response rate de-risks further clinical development and strengthens the rationale for advancing the asset into subsequent development phases or strategic partnerships.

Investors and healthcare researchers will look ahead to October 24, 2026, when additional poster details from the Phase 2 trial are scheduled for presentation at a medical conference. Future developments will also depend on potential partnership opportunities or larger controlled trials to further confirm the vaccine's efficacy.

## Key points

- All patients followed at three years in the Phase 2 melanoma trial maintained responses with no tumor progression.
- EVX-01 was administered as a stand-alone therapy during the third year of the trial.
- Prior two-year trial data showed a 75% overall response rate and a 25% complete response rate.
- Detailed study findings will be presented during a poster session on October 24, 2026.

## Questions and answers

### What were the three-year results for Evaxion's EVX-01 melanoma trial?

At the three-year mark, all patients monitored in the Phase 2 trial maintained their previous responses with no tumor progression, even while receiving EVX-01 as a stand-alone therapy during year three.

### What were the earlier Phase 2 response rates for EVX-01?

Two-year trial data showed a 75% overall response rate, with 25% of patients achieving a complete response and 92% of responding patients maintaining their response.

### When will Evaxion present the complete Phase 2 EVX-01 study data?

Evaxion is scheduled to present a poster with detailed Phase 2 trial results on October 24, 2026.